Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

03162022-Johns-Hopkins-human-serum-project

ABSTRACT: Human serum samples from Johns Hopkins University. LCMS run on 03-16-2022. Polar C18 column.

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Human Serum

SUBMITTER: Dr. McCall

PROVIDER: MSV000089087 | MassIVE | Mon Mar 21 08:04:00 GMT 2022

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Similar Datasets

05092023-neg-pc18-data-backup-JH-human-serum-project

Project description:Human serum samples from Johns Hopkins University. LCMS run on 05-09-2023. Polar C18 column in negative mode. This project is about the chagas disease progression. Four groups in this dataset: infected-progressed, infected-non-progressed, uninfected-progressed, uninfected-non-progressed. We want to compare the progressed and non-progressed in infected groups to see the changes of metabolites related to the disease progression.

2023-08-25 | MSV000092758 | MassIVE

05092023-pos-pc18-data-backup-JH-human-serum-project

Project description:Human serum samples from Johns Hopkins University. LCMS run on 05-09-2023. Polar C18 column in positive mode. This project is about the chagas disease progression. Four groups in this dataset: infected-progressed, infected-non-progressed, uninfected-progressed, uninfected-non-progressed. We want to compare the progressed and non-progressed in infected groups to see the changes of metabolites related to the disease progression.

2023-08-25 | MSV000092757 | MassIVE

05092023-pos-philic-data-backup

Project description:Human serum samples from Johns Hopkins University. LCMS run on 05-09-2023. Polar HILIC column. This project is about the chagas disease progression. Four groups in this dataset: infected-progressed, infected-non-progressed, uninfected-progressed, uninfected-non-progressed. We want to compare the progressed and non-progressed in infected groups to see the changes of metabolites related to the disease progression.

2023-08-25 | MSV000092754 | MassIVE

05092023-neg-philic-data-backup

Project description:Human serum samples from Johns Hopkins University. LCMS run on 05-09-2023. Polar HILIC column in negative mode. This project is about the chagas disease progression. Four groups in this dataset: infected-progressed, infected-non-progressed, uninfected-progressed, uninfected-non-progressed. We want to compare the progressed and non-progressed in infected groups to see the changes of metabolites related to the disease progression.

2023-08-25 | MSV000092756 | MassIVE

The Cancer of the Pancreas Screening-5 CAPS5)Study

Project description:Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

| 2156010 | ecrin-mdr-crc

john-hopkins-human-serum-data-backup-PRM-neg-philic

Project description:Project is john hopkins humna serum project, this project we try to search the biomarker candidates by comparing infected progressors and infected non-progressors. This is data backup for the negative mode polar HILIC column dataset.

2023-12-30 | MSV000093741 | MassIVE

john-hopkins-human-serum-data-backup-PRM-pos-philic

2023-12-30 | MSV000093740 | MassIVE

john-hopkins-human-serum-data-backup-PRM-neg-pc18

2023-12-30 | MSV000093743 | MassIVE

john-hopkins-human-serum-data-backup-PRM-pos-pc18

2023-12-30 | MSV000093742 | MassIVE

Expression data of candidates for prostate cancer active surveillance

Project description:The dataset consists of 266 NCCN very low/low or favorable-intermediate risk PCa patients who underwent diagnostic prostate biopsy between 2000 and 2014 and were treated with RP in six community or academic practices: University of Calgary, Cedars-Sinai, Spectrum Health, Cleveland Clinic, MD Anderson Cancer Center and Johns Hopkins. All patients had complete tumor pathology from biopsy and prostatectomy. Low risk PCa was defined as T1c or cT2a, and Gleason score (GS) ≤ 6, and PSA < 10ng/ml and favorable-intermediate risk was no greater than predominant GS 3 and percent positive biopsy cores < 50%, and either cT2b-cT2c or PSA 10-20ng/ml.

2018-09-08 | GSE119616 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data